Pre-Test Therapeutic Sequencing in Advanced Colorectal Cancer: New Strategies from Clinical Trial Data Pre-Test Current NCCN practice guidelines recommend which of these times as the earliest appropriate moment for comprehensive testing of RAS/NRAS/BRAF mutations, HER2 (ERBB2) amplification, and MSI-H or dMMR? Diagnosis Metastasis Progression Screening Unsure Which of the following combination treatments against refractory mCRC exhibited a median OS of 10.8 months versus 7.5 months in the control arm and a 56% relative risk reduction in the recent phase 3 SUNLIGHT clinical trial? encorafenib + cetuximab fruquintinib + pembrolizumab regorafenib + nivolumab trifluridine/tipiracil + bevacizumab Unsure Which of the following single agents is a potent VEGF-receptor inhibitor currently in the phase 3 FRESCO trial in which it exhibited a reduced risk of progression or death of 68% (0.32 HR) in a median duration of follow-up of 11 months? encorafenib fruquintinib regorafenib trifluridine/tipiracil Unsure Genetic mutations in which of the following pathways are a predictive marker of resistance to anti-EGFR therapy in patients with CRC? dMMR/MSI-H MAPK/PIK3 NRG1 VEGF Unsure How confident are you in your ability to match diagnostic biomarkers to specific targeted treatments in patients with CRC? Very confident Confident Somewhat confident Not very confident Not at all confident
